Article info

Original research
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

Authors

  1. Correspondence to Dr Robert I Haddad; Robert_Haddad{at}dfci.harvard.edu
View Full Text

Citation

Haddad RI, Seiwert TY, Chow LQM, et al
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

Publication history

  • Accepted January 18, 2022
  • First published February 25, 2022.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.